Innovative cancer treatment business Sirtex Medical Limited (ASX: SRX) has been on a wild ride recently as the market struggles to assess its potential to deliver a step change in sales growth of its SIR-Spheres radiation therapy.
The biotech's potential means it has an evangelical-like following among fund managers and retail investors alike and today the company disclosed some further news as to its expectations for the year ahead.
The business is set to present the results of its latest SIRFLOX trial at the American Society of Clinical Oncology (ASCO) on May 30, and today announced that it has snagged a prime presentation spot.
However, the salient information disclosed may be contained in the following statement:
"Until the peer review and validation process has been completed at the ASCO meeting, Sirtex is unable to assess the commercial impact of the SIRFLOX study results".
Evidently the company still feels the SIRFLOX trial results may have the potential to deliver some significant commercial sales growth for the business, but investors should be wary of the risks as demonstrated by its recent crash.
